Comparative effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and meta-analysis
In Medicine, Jayadevappa, Schwartz, and colleagues analyzed the comparative effectiveness of localized prostate cancer treatments (active surveillance, radical prostatectomy, and radiation therapy) through systematic review and meta-analysis. They focused on outcomes that matter most to newly diagnosed patients: mortality; cancer recurrence; disease and treatment complications; side effects; and patient-reported outcomes such as health-related quality of life, satisfaction with care, and decision regrets. The systematic review included 58 articles published from 1995-2016, (29...
Implementation of the laborist model was associated with a 15% decrease in the odds of the induction of labor and a 17% decrease in the odds of preterm birth.
A diverse set of national leaders and stakeholders representing industry, think-tanks, provider and patient groups, and academic experts discussed how health systems, payers, and providers can spur the ‘de-adoption’ of medical practices and technologies no longer considered valuable.
Developing a value framework for cancer drugs can sound like an arcane exercise without much relevance to clinical care. Restate it as a question of how, and how much, to pay for cancer drugs, and you’ve got everyone’s attention.
“Pay more for drugs that do more.” Although few would argue with the concept of paying for value, the mechanism for doing so has thus far eluded our multi-payer, market-based system. The Gant Precision Cancer Medicine Consortium at the University of Pennsylvania looked past US borders to learn about mechanisms in other countries, in its quest to recommend sustainable frameworks for valuing precision cancer drugs.
The eye-popping price tags on some new cancer drugs pose two fundamental questions: are the drugs worth their cost, and if they are, how can we afford them? The Penn Precision Cancer Medicine Consortium considered cost trends and drivers in the second of its conference calls leading up to an in-person conference in May.